Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key De... (alfa-2b) for hepatitisC and LymphoStat-B...)

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

Date:11/6/2008

alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is awaiting authorization to begin the delivery of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
2. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
3. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
4. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
5. Human Pheromone Sciences, Inc. - Shareholder Update
6. The human brain minimizes energy expenditure and integrates gravity in to the action plan
7. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
8. Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs
9. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
10. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference

Post Your Comments:

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key De...(alfa-2b) for hepatitisC and LymphoStat-B...)